| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.0087 | 0.9 |
| mRNA | AZD0530 | FIMM | pan-cancer | AAC | 0.011 | 0.9 |